1Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
2Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Copyright © 2014 by the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Characteristic | No. of patients | KRAS | ||
---|---|---|---|---|
MT (n=19) | WT (n=13) | p-value | ||
Age (yr) | ||||
Median (range) | 53.5 (20-70) | |||
Gender | ||||
Male | 23 | 12 | 11 | 0.25 |
Female | 9 | 7 | 2 | |
ECOG performance status | ||||
0-1 | 32 | 19 | 13 | - |
Primary site of tumor | ||||
Right | 10 | 5 | 5 | 0.70 |
Left | 22 | 14 | 8 | |
Tumor grade | ||||
Well | 9 | 8 | 1 | 0.05 |
Moderate/Poor | 23 | 11 | 12 | |
Prior adjuvant chemotherapy | 9 | 4 | 5 | 0.24 |
Metastasized sites | ||||
Lung | 17 | 10 | 7 | 0.65 |
Liver | 17 | 11 | 6 | 0.78 |
Lymph nodes | 15 | 8 | 7 | 0.31 |
Peritoneum | 8 | 6 | 2 | 0.68 |
Bladder | 1 | 0 | 1 | 0.38 |
Ovary | 1 | 1 | 0 | 0.63 |
Bone | 3 | 1 | 2 | 0.54 |
No. of metastatic sites | ||||
≤2 | 25 | 15 | 10 | 0.61 |
≥2 | 7 | 4 | 3 | |
Ascites/Pleural effusion | 1 | 1 | 0 | 0.63 |
Hydronephrosis | 1 | 0 | 1 | 0.38 |
Anti-EGFR therapies | 6 | 0 | 6 | 0.01 |
First-line therapy including anti-VEGF (n=32) | Second-line therapy (n=28) | |||||
---|---|---|---|---|---|---|
KRAS WT (n=13) | KRAS MT (n=19) | KRAS WT (n=13) | KRAS MT (n=15) | |||
Complete response | - | - | 1 | - | ||
Partial response | 6 | 10 | 3 | 3 | ||
Stable disease | 5 | 6 | 3 | 9 | ||
Progressive disease | 2 | 3 | 6 | 3 | ||
Overall response rate | 46.2 | 52.6 | 30.8 | 20 | ||
p-value | 0.72 | 0.67 |
Prognostic marker | Hazard ratio | 95% CI | p-value |
---|---|---|---|
PFS for anti-VEGF plus oxaliplatin based chemotherapy | |||
Age (≤65 yr vs. >65 yr) | 1.537 | 0.649-3.637 | 0.328 |
Gender (female vs. male) | 2.353 | 0.966-5.732 | 0.060 |
Site (left vs. right) | 1.461 | 0.635-3.363 | 0.373 |
Grade (well vs. moderate/poor) | 0.634 | 0.251-1.598 | 0.334 |
Adjuvant chemotherapy (no vs. yes) | 0.771 | 0.332-1.790 | 0.545 |
No. of metastatic sites (≤2 vs. >2) | 0.774 | 0.306-1.955 | 0.588 |
Ascites/Pleural effusion (no vs. yes) | 0.674 | 0.089-5.118 | 0.703 |
Hydronephrosis (no vs. yes) | 1.641 | 0.219-12.276 | 0.630 |
KRAS mutation (no vs. yes) | 1.007 | 0.469-2.162 | 0.986 |
Response (yes vs. no) | 0.288 | 0.126-0.658 | 0.003 |
Overall survival | |||
Age (≤65 yr vs. >65 yr) | 0.921 | 0.370-2.298 | 0.861 |
Sex (female vs. male) | 0.700 | 0.271-1.803 | 0.460 |
Site (left vs. right) | 2.934 | 0.949-9.073 | 0.062 |
Grade (well vs. moderate/poor) | 0.569 | 0.220-1.470 | 0.244 |
Adjuvant chemotherapy (no vs. yes) | 1.319 | 0.517-3.363 | 0.563 |
No. of metastatic sites (≤2 vs. >2) | 0.158 | 0.045-0.555 | 0.004 |
Ascites/Pleural effusion (no vs. yes) | 2.038 | 0.266-15.613 | 0.493 |
Hydronephrosis (no vs. yes) | 0.399 | 0.050-3.158 | 0.384 |
KRAS mutation (no vs. yes) | 0.548 | 0.226-1.328 | 0.183 |
Anti-EGFR therapies (yes vs. no) | 0.742 | 0.268-2.056 | 0.566 |
MT, mutant; WT, wild type; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.
VEGF, vascular endothelial growth factor; WT, wild type; MT, mutant.
CRC, colorectal cancer; VEGF, vascular endothelial growth factor; CI, confidence interval; PFS, progression free survival; EGFR, epidermal growth factor receptor.